USP32 and breast carcinoma: Researchers further found that the direct binding of USP32 and SLC35F2 in the endoplasmic reticulum could negatively regulate the stability of SLC35F2 and promote drug resistance to YM155 in breast cancer cells [32] (Fig. 6).